BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Stock Information for Brainstorm Cell Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.